

Brisk Walking May Stress Knee Joints in the Obese

BY ROBERT FINN
San Francisco Bureau

DENVER — Brisk walking appears to place significant stress on knee joints, especially in obese individuals, and that may contribute to musculoskeletal injuries, Ray Browning, Ph.D., reported at the annual meeting of the American College of Sports Medicine.

When walking at 1.5 m/sec (3.4 mph), obese individuals experience about a 50%

greater amount of torque at the knee joint than do normal-weight individuals. That increased amount of torque disappears when obese individuals walk at 1 m/sec (2.2 mph).

Dr. Browning, a physiology researcher at the University of Colorado, Boulder, pointed to data from the Centers for Disease Control and Prevention indicating that about one in four obese patients suffer a musculoskeletal injury when they first start walking for exercise, and that

25% of those injured patients never return to exercise. He suggested that prescribing slower walking speeds to obese patients may, in part, alleviate this problem.

The study involved 10 obese patients with an average BMI of 35.5 kg/m², and 10 normal-weight individuals with an average BMI of 22 kg/m². They walked on a dual-belt, force-measuring treadmill at six speeds between 0.5-1.75 m/sec.

High-speed video in both the sagittal and frontal planes enabled the calculation

of ground reaction forces, and this in turn allowed the calculation of torque at the knee joint.

Dr. Browning attributed the increase in ground reaction forces and torque at the knee joint to the fact that obese individuals have a larger step width. In agreement with previous studies on the biomechanics of walking, the investigators found that individuals in the obese group took steps that were about 60% wider than the normal-weight individuals. ■

Start and stay with nonscheduled Rozerem— ZERO evidence of abuse or dependence

Clinical studies show no evidence
of potential abuse, dependence, or withdrawal*

- **First and only**—nonscheduled prescription insomnia medication... not a controlled substance and approved for long-term use¹
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle¹
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies¹
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression¹
- **Promote sleep with Rozerem**—patients who took Rozerem fell asleep faster than those who took placebo¹
- **One simple 8-mg dose**¹

*Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).^{1,2}

Please visit www.rozerem.com

 **Rozerem**™
ramelteon 8-mg tablets

*Proven for sleep.
Nonscheduled for added safety.*